KymaThera

Advancing the Next Wave of Precision Therapeutics

Watertown, United States · Founded 2024 · $148.0M raised

Employees
51–200
Founded
2024
Business Model
B2B
Total Funding
$148.0M
Last Round
$80.0M Series CDec 2022
Rounds
3

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

KymaThera develops best-in-class small-molecule medicines for serious diseases with high unmet medical need, using proprietary structure-based design. Its pipeline includes a mutant-selective PI3Kα oncology candidate that spares wild-type PI3Kα, a potent inhaled ALK5 inhibitor optimized for durable lung exposure in pulmonary fibrosis, and mutant-selective JAK2 inhibitors for myeloproliferative disorders. Programs target well-characterized, dysregulated proteins where scientific precision can improve on current therapies and deliver meaningful patient benefit.

Summary

KymaThera is a Biotech company based in Watertown, United States, founded in 2024. It has raised $148.0M in total across 3 rounds, most recently a $80.0M Series C round in Dec 2022. Investors include Venrock, Sands Capital and Cormorant Asset Management.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series CSeries CDec 2022
$80.0M

Sign up to see all 3 events

Funding: Series A through Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

KymaThera on Indexed.vc
<a href="https://indexed.vc/companies/kymathera"><img src="https://indexed.vc/api/badge/company/kymathera" alt="KymaThera on Indexed.vc" width="260" height="76" /></a>